49% in 10 (10.5%), and 50% in 26 (27.4%) and unknown in 55 (57.9%). The objective response rate (ORR) was 35.0% (CR: 0, PR: 7, SD: 6, PD: 5, NE: 2), the median progression-free survival (PFS) was 6.1 months [95% confidence interval (CI): 1.6-7.7], and the median survival time (MST) was 8.7 months [95% CI: 7.9-not reached (NR)] for first-line treatment in patients with TPS 50%. The ORR was 20.0% (CR: 0, PR: 15, SD: 18, PD: 31, and NE: 11), the PFS was 2.9 months [95% CI: 1.9-4.6], and the MST was 15.5 months [95% CI: 5.5-NR] for second-or later-line treatment. The median G8 score was 11.5 (range: 5.5-15.5). The MST was longer in the G8 high (>11.5) group than the low (11.5) group (NR vs. 8.2 months) (p ¼ 0.02). Likewise, the MST was 17.8 months (PS 0-1) vs. 3.1 months (PS 2) (p < 0.01). The grade 2 immune-related adverse events incidence was 23.3% (thyroid disease: 4.2%; interstitial lung disease: 10.5%). Conclusions: Although the observation period is short and the data is immature, ICIs were effective and tolerable for patients aged 75 years. PS is a simple and exact parameter, but G8 screening is also useful in judging ICI adequacy for the elderly. Legal entity responsible for the study: Okayama University Hospital. Funding: Has not received any funding.
1474P Nivolumab in non-small cell lung cancer: French evaluation of use, current practices and medico-economic approach Results: 377 pts with squamous (113 pts), non-squamous (197) and undifferentiated (67) NSCLC have been included. The median number of courses was 8 (1-54). 140 pts (37%) had 1 to 4 courses, 67 pts (18%) 5 to 8 courses and 170 pts (45%) more than 8. 247 pts were treated in 2 nd line, 98 in 3 rd line. All lines combined, CB was experienced by 212 pts (56%). For these pts, median course was 17 (1-54), mPFS and mOS were 4.6 months and 15.0 months, respectively. No difference on survival has been noticed according to histology, treatment line, age (cut-off 70 y), grade III/IV toxicity. However, mPFS and mOS were lower in ECOG PS 2 pts than in PS0-1 pts: 2.4 months vs 4.6 m (p < 0.01) for PFS and 3.7 m vs 15.0 m (p < 0.001) for OS. 20% of pts presented grade III/IV toxicities. These pts presented a better CB (74% vs 56%, p ¼ 0.002). In 2016-2017, this treatment, for pts initiated in 2016 only, cost 15.8 million euros (drug, hospitalisation and transportation). 86% of these costs were dedicated to pts who experienced CB. Conclusions: In a real-life setting, survival outcomes and toxicities with nivolumab in advanced NSCLC are comparable to literature data. ECOG PS 2 pts presented shorter survival than PS0-1 pts. Interestingly, 86% of the cost incurred for these treatments was to pts with CB. Updated data will be shown at the meeting. Background: With the wide introduction of anti-PD-1 agents in the treatment of NSCLC, the unusual patterns of response are now observed more frequently in the clinical setting. One of the major concerns for clinicians is hyperprogression, perceived as a reality by many but for which there is still discussion and has no standard definition. The aim of our work was to analyse the patterns of response to nivolumab in a homogeneously treated population of patients with NSCLC and identify cases with hyperprogression. Methods: Between December 2015 and August 2017, 42 patients with NSCLC were treated with Nivolumab at 3mg/kg every 2 weeks. A retrospective evaluation of the CT scans (previous to baseline, baseline before nivolumab, subsequent scans after nivolumab) was performed by a thoracic radiologist. Tumour growth rate was defined as the percentage of variation by RECIST1.1 over time. It was calculated for the pre and postnivolumab period (RECIST%/time (days)). We defined hyperprogressors as those patients whose tumour growth was 2 times greater on nivolumab than in the pre-nivolumab period. Results: RECIST 1.1 evaluation was feasible in 40 patients. Best response was a partial response in 17.5% patients, including 4 cases (10%) of pseudoprogression and 2 cases with delayed response (after 1st scan). Thirty percent and 52.5% of patients showed stable disease and progressive disease, respectively. Among the 20 patients who developed progression by RECIST 1.1 on nivolumab, 16 experienced a more rapid progression in the post-nivolumab period (median % of change/t 0.6 Vs 0.3 in the pre-nivolumab period; p ¼ 0.02)). Sixty percent (12/20) of progressing patients were hyperprogressors according to our definition (30% of the total population). No differences between hyperprogressors vs rest of progressors according to age, performance status, treatment line, gender or histology was observed. Conclusions: Rare patterns of response (pseudoprogression, hyperprogression) must be considered in the evaluation of patients treated with immunotherapy. Unexpectedly rapid progressions are observed on immunotherapy. Standardized definitions and mechanisms for these events warrant further investigation. Legal entity responsible for the study: Hospital del Mar. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. Background: To assess the role of I for second line treatment of APNS-NSCLC. Methods: A pooled analysis of the final data of the CA209057, the KEYNOTE-010 and the OAK trial was performed. Overall Survival (OS) was the primary end point of the trial. The outcomes of patients with PD-L1 expression of 1%-49% (PD-L1 1%-49%), PD-L1 expression <1% (PD-L1<1%) or mutated-EGFR (EGFRþ) were analyzed comparing any checkpoint inhibitor with standard chemotherapy. An indirect comparison with network meta-analysis was performed between the different checkpoint inhibitors whenever a significant difference was observed in the pooled analysis. Direct and indirect comparisons were performed using a random effect model. Results: The outcome of 1720 patients was analyzed. 313 patients had been treated with Atezolizumab (A), 292 with Nivolumab (N), 270 with Pembrolizumab (P), and 845 
